DrugCite
Search

EFAVIRENZ

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Efavirenz Adverse Events Reported to the FDA Over Time

How are Efavirenz adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Efavirenz, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Efavirenz is flagged as the suspect drug causing the adverse event.

Most Common Efavirenz Adverse Events Reported to the FDA

What are the most common Efavirenz adverse events reported to the FDA?

Immune Reconstitution Syndrome
341 (2.58%)
Pyrexia
230 (1.74%)
Drug Exposure During Pregnancy
197 (1.49%)
Pregnancy
183 (1.38%)
Vomiting
170 (1.29%)
Anaemia
161 (1.22%)
Diarrhoea
124 (.94%)
Hepatitis
123 (.93%)
Abortion Spontaneous
107 (.81%)
Nausea
106 (.8%)
Alanine Aminotransferase Increased
99 (.75%)
Show More Show More
Rash
99 (.75%)
Confusional State
95 (.72%)
Drug Interaction
95 (.72%)
Lactic Acidosis
91 (.69%)
Lipodystrophy Acquired
90 (.68%)
Asthenia
89 (.67%)
Aspartate Aminotransferase Increase...
87 (.66%)
Abdominal Pain
83 (.63%)
Headache
81 (.61%)
Dyspnoea
79 (.6%)
Cough
77 (.58%)
Lymphadenopathy
76 (.57%)
Blood Alkaline Phosphatase Increase...
67 (.51%)
Dizziness
67 (.51%)
Death
66 (.5%)
Haemoglobin Decreased
66 (.5%)
Dehydration
65 (.49%)
Renal Failure Acute
64 (.48%)
Hepatic Function Abnormal
61 (.46%)
Cardiac Malposition
59 (.45%)
Abortion Induced
57 (.43%)
Eyelid Ptosis
57 (.43%)
Malaise
57 (.43%)
Depression
56 (.42%)
Mitochondrial Toxicity
56 (.42%)
Weight Decreased
56 (.42%)
Tuberculosis
55 (.42%)
Drug Resistance
54 (.41%)
Neutropenia
54 (.41%)
Sepsis
54 (.41%)
Gamma-glutamyltransferase Increased
52 (.39%)
Portal Hypertension
52 (.39%)
Liver Disorder
51 (.39%)
Deformity Thorax
50 (.38%)
Fatigue
50 (.38%)
Pain In Extremity
49 (.37%)
Exomphalos
48 (.36%)
Hypertension
48 (.36%)
Jaundice
48 (.36%)
Diaphragmatic Aplasia
47 (.36%)
Diplopia
47 (.36%)
Hyperlipidaemia
47 (.36%)
Renal Impairment
47 (.36%)
Hepatic Encephalopathy
46 (.35%)
Pulmonary Tuberculosis
46 (.35%)
Pneumonia
45 (.34%)
Hepatic Displacement
44 (.33%)
Hepatotoxicity
42 (.32%)
Progressive External Ophthalmoplegi...
42 (.32%)
Premature Baby
41 (.31%)
Stillbirth
41 (.31%)
Vanishing Bile Duct Syndrome
41 (.31%)
Agitation
40 (.3%)
Hepatic Cirrhosis
40 (.3%)
Renal Failure
40 (.3%)
Ascites
39 (.3%)
Blood Bilirubin Increased
39 (.3%)
Fall
39 (.3%)
Drug Toxicity
38 (.29%)
Cachexia
37 (.28%)
Condition Aggravated
37 (.28%)
Congenital Anomaly
37 (.28%)
Hepatomegaly
37 (.28%)
Hypersensitivity
37 (.28%)
Maternal Drugs Affecting Foetus
37 (.28%)
Pancytopenia
37 (.28%)
Respiratory Failure
37 (.28%)
Gastroenteritis
36 (.27%)
Myocardial Infarction
36 (.27%)
Anorexia
35 (.26%)
Cholestasis
35 (.26%)
Convulsion
35 (.26%)
Neuropathy Peripheral
35 (.26%)
Aids Encephalopathy
31 (.23%)
Suicidal Ideation
31 (.23%)
Decreased Appetite
30 (.23%)
Hyperlactacidaemia
30 (.23%)
Hypokalaemia
30 (.23%)
Metabolic Acidosis
30 (.23%)
Pain
30 (.23%)
Drug Ineffective
29 (.22%)
Hallucination
29 (.22%)
Hepatic Failure
29 (.22%)
Hepatitis C
29 (.22%)
Insomnia
29 (.22%)
General Physical Health Deteriorati...
28 (.21%)
Diabetes Mellitus
27 (.2%)
Head Circumference Abnormal
27 (.2%)
Hepatosplenomegaly
27 (.2%)
Lipoatrophy
27 (.2%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Efavirenz, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Efavirenz is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Efavirenz

What are the most common Efavirenz adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Efavirenz, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Efavirenz is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Efavirenz According to Those Reporting Adverse Events

Why are people taking Efavirenz, according to those reporting adverse events to the FDA?

Hiv Infection
3349
Antiretroviral Therapy
172
Acquired Immunodeficiency Syndrome
132
Drug Use For Unknown Indication
95
Drug Exposure During Pregnancy
91
Hiv Test Positive
50
Show More Show More
Prophylaxis Against Hiv Infection
43
Product Used For Unknown Indication
25
Systemic Antiviral Treatment
17
Retroviral Infection
11
Antiviral Treatment
8
Ill-defined Disorder
5
Pneumocystis Jiroveci Pneumonia
4
Asymptomatic Hiv Infection
4
Antiviral Prophylaxis
4
Viral Infection
4
Prophylaxis
3
Hiv Infection Cdc Group Iv Subgroup...
3
Hypertension
3
Hiv Test
3
Acute Hiv Infection
3
Vertical Infection Transmission
3
Immunodeficiency
2
Maternal Exposure Timing Unspecifie...
2
Hepatitis C
2
Progressive Multifocal Leukoencepha...
2
Infection
2
Hiv Infection Cdc Category C3
2
Hiv Infection Cdc Group Iv Subgroup...
1
Hiv Infection Cdc Category A3
1
Hiv Infection Cdc Group Iv Subgroup...
1
Hiv Antigen Positive
1
Anti-infective Therapy
1
Antibiotic Prophylaxis
1
Platelet Aggregation Inhibition
1
Kaposis Sarcoma Aids Related
1
Hiv Infection Cdc Category A1
1
Cd4 Lymphocytes Decreased
1
Hiv Infection Cdc Category B3
1
Tuberculosis
1
Urticaria
1
Histoplasmosis Disseminated
1
Platelet Count Decreased
1
Hiv Infection Cdc Group I
1
Infection Prophylaxis
1
Hepatitis B Virus Test
1
Drug Level
1

Drug Labels

LabelLabelerEffective
AtriplaState of Florida DOH Central Pharmacy12-MAR-10
AtriplaLake Erie Medical DBA Quality Care Products LLC13-NOV-12
SustivaBristol-Myers Squibb Pharma Company01-JAN-13
SustivaPhysicians Total Care, Inc.02-JAN-13
AtriplaBristol Myers Squibb & Gilead Sciences, LLC16-JAN-13
AtriplaREMEDYREPACK INC. 29-MAR-13
AtriplaBristol Myers Squibb & Gilead Sciences, LLC23-APR-13

Efavirenz Case Reports

What Efavirenz safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Efavirenz. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Efavirenz.